180 related articles for article (PubMed ID: 9517948)
21. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
MacGowan AP; Rogers CA; Holt HA; Bowker KE
Antimicrob Agents Chemother; 2003 Mar; 47(3):1088-95. PubMed ID: 12604546
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Scaglione F; Mouton JW; Mattina R; Fraschini F
Antimicrob Agents Chemother; 2003 Sep; 47(9):2749-55. PubMed ID: 12936969
[TBL] [Abstract][Full Text] [Related]
23. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister PD; Sanders CC
Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
[TBL] [Abstract][Full Text] [Related]
25. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
[TBL] [Abstract][Full Text] [Related]
26. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model.
Firsov AA; Lubenko IY; Portnoy YA; Zinner SH; Vostrov SN
Antimicrob Agents Chemother; 2001 Mar; 45(3):927-31. PubMed ID: 11181382
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
[TBL] [Abstract][Full Text] [Related]
28. Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.
Bowker KE; Wootton M; Rogers CA; Lewis R; Holt HA; MacGowan AP
J Antimicrob Chemother; 1999 Nov; 44(5):661-7. PubMed ID: 10552983
[TBL] [Abstract][Full Text] [Related]
29. In vitro characterization of fluoroquinolone concentration/MIC antimicrobial activity and resistance while simulating clinical pharmacokinetics of levofloxacin, ofloxacin, or ciprofloxacin against Streptococcus pneumoniae.
Madaras-Kelly KJ; Demasters TA
Diagn Microbiol Infect Dis; 2000 Aug; 37(4):253-60. PubMed ID: 10974576
[TBL] [Abstract][Full Text] [Related]
30. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
Portnoy YA; Vostrov SN; Lubenko IY; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
[TBL] [Abstract][Full Text] [Related]
31. [The pharmacodynamics and pharmacokinetics of fluoroquinolones in the evaluation of antibacterial therapy regimens].
Smirnova LB; Sokolova VI
Antibiot Khimioter; 2000; 45(7):14-6. PubMed ID: 10987102
[TBL] [Abstract][Full Text] [Related]
32. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
Ba BB; Feghali H; Arpin C; Saux MC; Quentin C
Antimicrob Agents Chemother; 2004 Mar; 48(3):946-53. PubMed ID: 14982788
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection.
Ernst EJ; Klepser ME; Petzold CR; Doern GV
Pharmacotherapy; 2002 Apr; 22(4):463-70. PubMed ID: 11939681
[TBL] [Abstract][Full Text] [Related]
35. Differential selection of multidrug efflux mutants by trovafloxacin and ciprofloxacin in an experimental model of Pseudomonas aeruginosa acute pneumonia in rats.
Join-Lambert OF; Michéa-Hamzehpour M; Köhler T; Chau F; Faurisson F; Dautrey S; Vissuzaine C; Carbon C; Pechère J
Antimicrob Agents Chemother; 2001 Feb; 45(2):571-6. PubMed ID: 11158756
[TBL] [Abstract][Full Text] [Related]
36. [Effect of efflux pump inhibitor 1-(1-naphthylmethyl)-piperazine to MIC values of ciprofloxacin in ciprofloxacin resistant gram-negative bacteria].
Coban AY; Bayram Z; Sezgin FM; Durupinar B
Mikrobiyol Bul; 2009 Jul; 43(3):457-61. PubMed ID: 19795621
[TBL] [Abstract][Full Text] [Related]
37. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
Strukova EN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
[TBL] [Abstract][Full Text] [Related]
39. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?
Strukova EN; Portnoy YA; Zinner SH; Firsov AA
J Chemother; 2017 Dec; 29(6):351-357. PubMed ID: 28587559
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
Peterson ML; Hovde LB; Wright DH; Brown GH; Hoang AD; Rotschafer JC
Antimicrob Agents Chemother; 2002 Jan; 46(1):203-10. PubMed ID: 11751135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
